@article{8f28ec3827594437802777979ebfdb66,
title = "Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis",
abstract = "Hexanucleotide repeat expansions in C9ORF72 are a common cause of familial and apparently sporadic amyotrophic lateral sclerosis (ALS) and frontal temporal dementia (FTD). The mechanism by which expansions cause neurodegeneration is unknown, but current evidence supports both loss-of-function and gain-of-function mechanisms. We used pooled next-generation sequencing of the C9ORF72 gene in 389 ALS patients to look for traditional loss-of-function mutations. Although rare variants were identified, none were likely to be pathogenic, suggesting that mutations other than the repeat expansion are not a common cause of ALS, and providing supportive evidence for a gain-of-function mechanism. We also show by repeat-primed PCR genotyping that the C9ORF72 expansion frequency varies by geographical region within the United States, with an unexpectedly high frequency in the Mid-West. Finally we also show evidence of somatic instability of the expansion size by Southern blot, with the largest expansions occurring in brain tissue.",
keywords = "Amyotrophic lateral sclerosis, C9ORF72, C9ORF72 hexanucleotide repeat, Genetics",
author = "Harms, {Matthew B.} and Janet Cady and Craig Zaidman and Paul Cooper and Taha Bali and Peggy Allred and Carlos Cruchaga and Michael Baughn and Libby, {Ryan T.} and Alan Pestronk and Alison Goate and John Ravits and Baloh, {Robert H.}",
note = "Funding Information: M.H. receives research support from the National Institutes of Health and the Millstone Family Foundation; participates in studies funded by the Jain Foundation, Ultragenyx, and Biogen-Idec; and has provided expert testimony in medical-legal proceedings unrelated to this topic. A.P. receives revenue related to antibody patent licenses and speaker honoraria from Athena; owns stock in Johnson & Johnson; Directs the Washington University Neuromuscular Clinical Laboratory which performs antibody testing; receives research support from the National Institutes of Health, Muscular Dystrophy Association, Neuromuscular Research Fund; Insmed, Knopp, Cytokinetics, Biogen Idec, ISIS, Genzyme, GSK, Sanofi, and Ultragenyx. A.G. receives revenue from expert testimony, consulting, or speaking from Pfizer, Genentech, Finnegan, and Amgen. She receives royalties from a patent license to Taconic and research support from Genentech, Pfizer, and the Barnes Jewish Foundation. J.R. receives research support from the ALS Association, Microsoft Research, and P2ALS; serves as an unpaid consultant to the Muscular Dystrophy Association; and consults for Isis Pharmaceuticals, Inc. None of the other authors have anything to disclose. Funding Information: This work was supported by National Institutes of Health (NIH) grants NS069669 (R.H.B) and K08NS075094 (M.B.H.), as well as the Hope Center for Neurological Disorders. R.H.B. holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. This publication was made possible by grant UL1 RR024992 from the National Center for Research Resources (NCRR) , a component of the NIH, and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The authors thank the Transgenic Vectors Core at the Hope Center for Neurological Disorders for assistance in developing the Southern blot method, the Genome Technology Access Center for assistance with library preparation and sequencing, and the Dr. Todd Druley laboratory for their technical expertise and assistance in implementing SPLINTER. The authors also thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). DNA panels from the NINDS Human Genetics Resource Center DNA and Cell Line Repository ( http://ccr.coriell.org/ninds ) were used in this study, as well as clinical data. The submitters that contributed samples are acknowledged in detailed descriptions of each panel: NDPT020, NDPT025, NDPT026, NDPT079, NDPT82, NDPT095, NDPT096, NDPT100, NDPT103, NDPT106, and NDPT116. ",
year = "2013",
month = sep,
doi = "10.1016/j.neurobiolaging.2013.03.006",
language = "English",
volume = "34",
pages = "2234.e13--2234.e19",
journal = "Neurobiology of Aging",
issn = "0197-4580",
number = "9",
}